<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02537314</url>
  </required_header>
  <id_info>
    <org_study_id>131032</org_study_id>
    <secondary_id>R01DK100431</secondary_id>
    <nct_id>NCT02537314</nct_id>
  </id_info>
  <brief_title>Role of the Foregut in Nutrient Metabolism in Lean and Obese Humans</brief_title>
  <official_title>Role of the Foregut in Nutrient Metabolism in Lean and Obese Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall hypothesis of this proposal is that nutrient sensing in the foregut regulates
      metabolic hormone secretion and nutrient metabolism via enteric neural signals, and these
      mechanisms might be defective in obesity.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastrointestinal Hormones</measure>
    <time_frame>5 Hours</time_frame>
    <description>Plasma levels of CCK, GIP, GLP-1, Ghrelin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pancreatic Hormones</measure>
    <time_frame>5 Hours</time_frame>
    <description>Plasma levels of Insulin, C-peptide, Glucagon</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose and Free Fatty Acids (FFAs)</measure>
    <time_frame>5 Hours</time_frame>
    <description>Plasma levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose Metabolism</measure>
    <time_frame>5 Hours</time_frame>
    <description>Glucose tracer kinetics ([3-3H] glucose and [U-13C] oleate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat Metabolism</measure>
    <time_frame>5 Hours</time_frame>
    <description>Oleate tracer kinetics ([U-13C] oleate)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Appetite, Hunger, and GI symptoms</measure>
    <time_frame>5 Hours</time_frame>
    <description>Visual Analog Scales (Likert)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>benzocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5% benzocaine solution in saline/HCl administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (saline) solution administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>benzocaine</intervention_name>
    <description>0.5% benzocaine solution in saline/HCl administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)</description>
    <arm_group_label>benzocaine</arm_group_label>
    <other_name>ethyl 4-aminobenzoate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo (saline) solution administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>NaCl, sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI 19 - 25 kg/m2 or 30 - 50 kg/m2

          -  Age 20 - 50 years

        Exclusion Criteria:

          -  Contraindication to a nasoduodenal feeding tube (e.g., deviated nasal septum, prior
             upper gastrointestinal bleed, or history of easy bleeding)

          -  Prior gastric or intestinal surgery or pancreas resection

          -  Females with a positive pregnancy test

          -  Known history of intestinal diseases including, but not limited to, inflammatory bowel
             disease (e.g. ulcerative colitis, Crohn's disease), celiac sprue

          -  Type 1 or type 2 diabetes

          -  Recent presence of or treatment for gastroenteritis (diarrhea and/or vomiting),
             constipation, or upper respiratory infection

          -  Anemia

          -  Abnormal EKG

          -  Prior adverse reaction to anesthesia

          -  Tobacco use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robyn A Tamboli, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Naji N Abumrad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2015</study_first_submitted>
  <study_first_submitted_qc>August 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2015</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Naji Abumrad</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Normal Body Weight</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Benzocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

